Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025
Lifecore Biomedical (NASDAQ: LFCR) will report financial results for the three months ended September 30, 2025 on Thursday, November 6, 2025 after market close.
Rhea-AI Summary
Lifecore Biomedical (NASDAQ: LFCR) will report financial results for the three months ended September 30, 2025 on Thursday, November 6, 2025 after market close.
Management will host a live webcast at 4:30 p.m. Eastern Time the same day to discuss results. To listen live or access the archived webcast (available for 30 days), visit the company’s Investor Events & Presentations page: https://ir.lifecore.com/events-presentations.
Positive
- None.
Negative
- None.
Details
News Market Reaction – LFCR
On Oct 31, the first trading day after this news, LFCR closed 1.27% above the previous close.
Data tracked by StockTitan Argus for the Oct 31 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Webcast Scheduled for Thursday, November 6 at 4:30 p.m. Eastern
CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the three months ended September 30, 2025, on Thursday, November 6, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team will host a webcast to discuss the results.
To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore’s website at: https://ir.lifecore.com/events-presentations. Following the live webcast, an archived version of the webcast will be available on the company’s website for 30 days.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
Lifecore Biomedical, Inc. Contact Information: Vida Strategic Partners Stephanie Diaz (Investors) 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) 415-675-7402 tbrons@vidasp.com Ryan D. Lake (CFO) Lifecore Biomedical 952-368-6244 ryan.lake@lifecore.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.